109 related articles for article (PubMed ID: 31242287)
1. HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
Becher OJ
Neuro Oncol; 2019 Sep; 21(9):1091-1092. PubMed ID: 31242287
[No Abstract] [Full Text] [Related]
2. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
3. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Shofuda T; Kanemura Y
Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
[No Abstract] [Full Text] [Related]
4. Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
Canettieri G; Di Marcotullio L; Coni S; Greco A; Gulino A
Cell Cycle; 2010 Jun; 9(11):2047-8. PubMed ID: 20505339
[No Abstract] [Full Text] [Related]
5. Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma.
Guerit S; Liebner S
Cancer Cell; 2016 Apr; 29(4):427-429. PubMed ID: 27070693
[TBL] [Abstract][Full Text] [Related]
6. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
7. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
8. Medulloblastoma: signalling a change in treatment.
Gilbertson RJ
Lancet Oncol; 2004 Apr; 5(4):209-18. PubMed ID: 15050952
[TBL] [Abstract][Full Text] [Related]
9. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
10. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
11. Hitting the target in medulloblastoma therapy.
Bradbury J
Drug Discov Today; 2004 Dec; 9(23):994-5. PubMed ID: 15574311
[No Abstract] [Full Text] [Related]
12. Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review.
Klinger PH; Andrade AF; Delsin LE; Queiroz RG; Scrideli CA; Tone LG; Valera ET
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218785
[TBL] [Abstract][Full Text] [Related]
13. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics.
Romer J; Curran T
Cancer Res; 2005 Jun; 65(12):4975-8. PubMed ID: 15958535
[TBL] [Abstract][Full Text] [Related]
14. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma growth inhibition by hedgehog pathway blockade.
Berman DM; Karhadkar SS; Hallahan AR; Pritchard JI; Eberhart CG; Watkins DN; Chen JK; Cooper MK; Taipale J; Olson JM; Beachy PA
Science; 2002 Aug; 297(5586):1559-61. PubMed ID: 12202832
[TBL] [Abstract][Full Text] [Related]
16. Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli.
Li XY; Zhou LF; Gao LJ; Wei Y; Xu SF; Chen FY; Huang WJ; Tan WF; Ye YP
Cancer Lett; 2018 Apr; 420():195-207. PubMed ID: 29425683
[TBL] [Abstract][Full Text] [Related]
17. Restore the brake on tumor progression.
Gordon RE; Zhang L; Yang ZJ
Biochem Pharmacol; 2017 Aug; 138():1-6. PubMed ID: 28389227
[TBL] [Abstract][Full Text] [Related]
18. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
19. The hedgehog pathway and neurological disorders.
Dellovade T; Romer JT; Curran T; Rubin LL
Annu Rev Neurosci; 2006; 29():539-63. PubMed ID: 16776596
[TBL] [Abstract][Full Text] [Related]
20. Medulloblastoma: novel insights into emerging therapeutic targets.
Shaik S; Maegawa S; Gopalakrishnan V
Expert Opin Ther Targets; 2021 Aug; 25(8):615-619. PubMed ID: 34602009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
